CareDx, Inc. Files Q2 2024 10-Q Report
Ticker: CDNA · Form: 10-Q · Filed: Jul 31, 2024 · CIK: 1217234
Sentiment: neutral
Topics: 10-Q, financials, medical-diagnostics
TL;DR
CareDx Q2 2024 10-Q is in. Financials and operations detailed. Check it out.
AI Summary
CareDx, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of 2024, detailing revenues from both its service and product segments. The filing also includes information on its business operations, legal proceedings, and risk factors.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for CareDx, Inc., crucial for understanding the company's current standing and future prospects in the medical diagnostics sector.
Risk Assessment
Risk Level: medium — The filing likely contains standard business risks, but without specific details on litigation or significant financial shifts, a medium risk level is assigned.
Key Numbers
- 2024 Q2 — Reporting Period (Second quarter of 2024 financial results)
- 2024-01-01 to 2024-06-30 — First Half 2024 (Year-to-date financial performance)
- 2023-01-01 to 2023-06-30 — First Half 2023 (Comparative year-to-date financial performance)
Key Players & Entities
- CareDx, Inc. (company) — Filer of the 10-Q report
- 20240630 (date) — End of the reporting period
- 20240731 (date) — Filing date
- XDxdx, Inc. (company) — Former company name
- EXPRESSION DIAGNOSTICS INC (company) — Former company name
FAQ
What were CareDx's total revenues for the second quarter of 2024?
The filing indicates financial results for the second quarter of 2024, but specific dollar amounts for total revenue are not detailed in this header information.
How did CareDx's service revenues compare between Q2 2024 and Q2 2023?
The filing specifies reporting periods for service revenue in Q2 2024 and Q2 2023, but the exact figures are not provided in this section.
What is the primary business segment for CareDx, Inc. according to the SIC code?
CareDx, Inc. is classified under SIC code 8071, which corresponds to SERVICES-MEDICAL LABORATORIES.
When was CareDx, Inc. previously known as XDxdx, Inc.?
The company's name was changed from XDxdx, Inc. on October 10, 2007.
What is the fiscal year end for CareDx, Inc.?
CareDx, Inc.'s fiscal year ends on December 31.
Filing Stats: 4,545 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-07-31 16:16:12
Key Financial Figures
- $0.001 — ich Registered Common Stock, par value $0.001 per share CDNA The Nasdaq Stock Market
Filing Documents
- cdna-20240630.htm (10-Q) — 1497KB
- cdna-20240630x10qxexx311.htm (EX-31.1) — 11KB
- cdna-20240630x10qxexx312.htm (EX-31.2) — 11KB
- cdna-20240630x10qxexx321.htm (EX-32.1) — 9KB
- 0001217234-24-000083.txt ( ) — 8590KB
- cdna-20240630.xsd (EX-101.SCH) — 60KB
- cdna-20240630_cal.xml (EX-101.CAL) — 99KB
- cdna-20240630_def.xml (EX-101.DEF) — 279KB
- cdna-20240630_lab.xml (EX-101.LAB) — 755KB
- cdna-20240630_pre.xml (EX-101.PRE) — 511KB
- cdna-20240630_htm.xml (XML) — 1335KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION 3
Unaudited Condensed Consolidated Financial Statements
Item 1. Unaudited Condensed Consolidated Financial Statements 3 Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023 4 Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 5 Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2024 and 2023 6 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 8 Notes to Unaudited Condensed Consolidated Financial Statements 9
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 32
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 48
Controls and Procedures
Item 4. Controls and Procedures 48
OTHER INFORMATION
PART II. OTHER INFORMATION 50
Legal Proceedings
Item 1. Legal Proceedings 50
Risk Factors
Item 1A. Risk Factors 50
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 58
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 58
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 59
Other Information
Item 5. Other Information 59
Exhibits
Item 6. Exhibits 60
Signatures
Signatures 62 2 Table of Contents
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CareDx, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except share data) June 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 95,782 $ 82,197 Marketable securities 133,089 153,221 Accounts receivable 66,161 51,061 Inventory 19,234 19,471 Prepaid and other current assets 6,343 7,763 Total current assets 320,609 313,713 Property and equipment, net 34,202 35,246 Operating leases right-of-use assets 27,188 29,891 Intangible assets, net 41,896 45,701 Goodwill 40,336 40,336 Restricted cash 588 586 Other assets 1,958 1,353 Total assets $ 466,777 $ 466,826 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 5,874 $ 12,872 Accrued compensation 25,004 19,703 Accrued and other liabilities 47,453 45,497 Total current liabilities 78,331 78,072 Deferred tax liability 50 136 Deferred payments for intangible assets 1,620 2,461 Operating lease liability, less current portion 25,386 28,278 Other liabilities 96,721 96,551 Total liabilities 202,108 205,498 Commitments and contingencies (Note 9) Stockholders' equity: Preferred stock: $ 0.001 par value; 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023 — — Common stock: $ 0.001 par value; 100,000,000 shares authorized at June 30, 2024 and December 31, 2023; 52,617,443 and 51,503,377 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 50 49 Additional paid-in capital 969,427 946,511 Accumulated other comprehensive loss ( 7,964 ) ( 6,963 ) Accumulated deficit ( 696,844 ) ( 678,269 ) Total stockholders' equity 264,669 261,328 Total liabilities and stockholders' equity $ 466,777 $ 466,826 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents CareDx, Inc. Cond